MedPath

Randomized Clinical Trial of an Exposure-based Cognitive Therapy for Depression

Phase 2
Conditions
Unipolar Depression
Interventions
Behavioral: Cognitive-Behavioral Therapy for Depression
Behavioral: Exposure-Based Cognitive Therapy for Depression
Registration Number
NCT01012856
Lead Sponsor
University of Zurich
Brief Summary

The purpose of this study is to investigate, if exposure-based cognitive therapy (EBCT) is at least as effective as the established cognitive-behavioral therapy and more effective in its long-term efficacy. Moreover the mechanisms of change of the EBCT are investigated.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
142
Inclusion Criteria
  • Major Depressive Disorder according to DSM-IV as main diagnosis
  • minimum standardized depression scores (BDI >= 17; HAMD >=13)
  • minimum age of 18 years
  • informed consent to participate voluntarily in the study
  • sufficient German language skills
Exclusion Criteria
  • acute suicidality
  • depressive disorder with mood-incongruent psychotic features
  • chronic depressive disorder
  • organic cause of depression
  • drug-induced depression
  • bipolar disorder
  • diagnosis of schizophrenia, schizophreniform, schizoaffective disorders, and/or psychosis NOS
  • comorbid dysthymia, psychotic disorder (acute or anamnestic), dementia, substance dependence, schizotypal/ borderline/ or antisocial personality disorder
  • psychopharmacological treatment other than antidepressants
  • antidepressant medication, if it is changed within one month prior to the beginning of psychotherapy
  • other simultaneous psychological treatments

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Cognitive-Behavioral Therapy for Depression (CBT)Cognitive-Behavioral Therapy for Depression-
Exposure-Based Cognitive Therapy for Depression (EBCT)Exposure-Based Cognitive Therapy for Depression-
Primary Outcome Measures
NameTimeMethod
severity of depressive symptoms measured by the Beck-Depression-Inventory (BDI-II)end of therapy, 6 month after end of therapy (follow up)
Secondary Outcome Measures
NameTimeMethod
symptom impairment measured by the Brief Symptom Inventory (BSI)end of therapy, 6-month follow up
quality of life measured by the WHO Quality of Life-BREF (WHOQOL-BREF)end of therapy, 6-month follow-up
interpersonal problems measured by the Inventory of Interpersonal Problems (IIP)end of therapy, 6-month follow-up
avoidance measured by the Cognitive-Behavioral Avoidance Scales (CBAS)end of therapy, 6-month follow-up
resources measured by the Bernese Inventory of Resources (RES-K)end of therapy, 6-month follow-up
explicit self-esteem measured by the Rosenberg self-esteem scale (RSES)end of therapy, 6-month follow up
implicit self-esteem measured by the Self-Esteem Implicit Association Test (SE-IAT)end of therapy
goal attainment measured by Goal Attainment Scaling (GAS)end of therapy
avoidance motivation measured by the Inventory of Approach and Avoidance Motivation (IAAM)end of therpy, 6-month follow-up
motivational incongruence measured by The Incongruence Questionnaire (INC)end of therapy, 6-month follow-up

Trial Locations

Locations (1)

University of Zurich, Department of Psychology

🇨🇭

Zurich, ZH, Switzerland

© Copyright 2025. All Rights Reserved by MedPath